Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2036-01-01 | Direct | 24,400 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 24,400 · Balance 24,400 F1: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2: This stock option becomes fully exercisable on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.
F2: This stock option becomes fully exercisable on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 24,400 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001193125-26-004355 · ownership.xml · derivative · entry 1 Verheyen Patrick · CIK 0001972605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Stock · 24,400 shares Expires 2036-01-01 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This stock option becomes fully exercisable on the first anniversary of the grant date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 24,400 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000950170-25-001103 · ownership.xml · derivative · entry 1 Verheyen Patrick · CIK 0001972605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Stock · 24,400 shares Expires 2035-01-01 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:01 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 24,400 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0000950170-24-001828 · ownership.xml · derivative · entry 1 Verheyen Patrick · CIK 0001972605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Stock · 24,400 shares Expires 2034-01-01 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 2, 2024. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 20:42 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001209191-23-024220 · doc4.xml · derivative · entry 1 Verheyen Patrick · CIK 0001972605 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-04-10 F1 · derivative.exercise_date: This stock option grant becomes exercisable over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.